Novel non-AR therapeutic targets in castrate resistant prostate cancer

Castrate resistant prostate cancer (CRPC) remains a disease with significant morbidity and mortality. The recent approval of abiraterone and enzalutamide highlight the improvements which can be made targeting the androgen receptor (AR) axis. Nonetheless, resistance inevitably develops and there is c...

Descripción completa

Detalles Bibliográficos
Autores principales: Toren, Paul J., Gleave, Martin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708177/
https://www.ncbi.nlm.nih.gov/pubmed/26816739
http://dx.doi.org/10.3978/j.issn.2223-4683.2013.09.09

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708177/
https://www.ncbi.nlm.nih.gov/pubmed/26816739
http://dx.doi.org/10.3978/j.issn.2223-4683.2013.09.09

Ejemplares similares